Skip to main content

Voglibose (Basen®, AO-128), One of the Most Important α-Glucosidase Inhibitors

Buy Article:

$63.00 plus tax (Refund Policy)

The number of people with diabetes is expected to rise from the current estimated 150 million to 220 million in 2010 and 300 million in 2025, and 90% is Type 2 diabetes or non-insulin dependant diabetes mellitus (NIDDM). Voglibose, one of the most important α-glucosidase inhibitors, delays the digestion and absorption of carbohydrates, thereby inhibiting postprandial hyperglycemia and hyperinsulinemia, and is the aid in the treatment of diabetes. In this paper, properties and the preparation of voglibose are reviewed.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Glucosidase inhibitor; NIDDM; Preparation; Voglibose

Document Type: Research Article

Affiliations: Institute of Bioengineering, Zhejiang University of Technology, Hangzhou 310032, PR China;

Publication date: 01 January 2006

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more